Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMY Bristol Myers Squibb	$47.10 -0.1%	$47.03	$42.96 ▼ $63.33	$95.90B	0.36	13.19 million shs	3.31 million shs
HZNP Horizon Therapeutics Public	$116.30	$115.72	$60.03 ▼ $116.38	$26.63B	1.03	2.50 million shs	N/A
RPRX Royalty Pharma	$35.82 -0.5%	$36.19	$24.05 ▼ $38.00	$20.91B	0.55	4.31 million shs	1.16 million shs
ZTS Zoetis	$155.03 -0.1%	$153.66	$139.70 ▼ $200.33	$68.74B	0.88	3.08 million shs	993,936 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMY Bristol Myers Squibb	-1.45%	-2.16%	-2.65%	+0.64%	-2.00%
HZNP Horizon Therapeutics Public	0.00%	0.00%	0.00%	0.00%	0.00%
RPRX Royalty Pharma	-0.91%	+0.19%	-1.85%	+10.09%	+27.67%
ZTS Zoetis	-0.78%	+1.85%	+2.09%	-6.69%	-14.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMY Bristol Myers Squibb	4.8047 of 5 stars	2.1	5.0	4.2	4.0	3.8	2.5	1.3
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	4.9781 of 5 stars	3.7	5.0	3.3	3.7	3.5	1.7	2.5
ZTS Zoetis	4.9179 of 5 stars	3.3	5.0	4.2	0.4	3.7	2.5	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMY Bristol Myers Squibb	2.24	Hold	$56.38	19.70% Upside
HZNP Horizon Therapeutics Public	0.00	N/A	N/A	N/A
RPRX Royalty Pharma	3.33	Buy	$48.00	34.01% Upside
ZTS Zoetis	2.50	Moderate Buy	$202.43	30.58% Upside

Current Analyst Ratings Breakdown

Latest HZNP, BMY, ZTS, and RPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZTS Zoetis	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$210.00 ➝ $215.00
8/5/2025	BMY Bristol Myers Squibb	Daiwa America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	BMY Bristol Myers Squibb	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$42.00
8/1/2025	BMY Bristol Myers Squibb	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$51.00 ➝ $47.00
7/31/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/22/2025	RPRX Royalty Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $42.00
7/17/2025	ZTS Zoetis	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/17/2025	ZTS Zoetis	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$180.00 ➝ $155.00
7/10/2025	RPRX Royalty Pharma	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$51.00 ➝ $54.00
7/10/2025	BMY Bristol Myers Squibb	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$36.00 ➝ $34.00
6/18/2025	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$165.00 ➝ $160.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMY Bristol Myers Squibb	$48.30B	1.98	$5.79 per share	8.14	$8.08 per share	5.83
HZNP Horizon Therapeutics Public	$3.63B	7.34	$7.05 per share	16.49	$22.38 per share	5.20
RPRX Royalty Pharma	$2.26B	9.23	$4.14 per share	8.66	$17.56 per share	2.04
ZTS Zoetis	$9.39B	7.32	$7.00 per share	22.15	$10.57 per share	14.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMY Bristol Myers Squibb	-$8.95B	$2.48	19.00	7.73	2.45	10.58%	80.04%	14.69%	10/30/2025 (Estimated)
HZNP Horizon Therapeutics Public	$521.48M	$1.87	62.19	20.55	3.96	12.02%	20.46%	11.52%	N/A
RPRX Royalty Pharma	$858.98M	$1.73	20.72	7.37	2.37	44.23%	25.54%	14.11%	11/5/2025 (Estimated)
ZTS Zoetis	$2.49B	$5.81	26.70	22.97	2.51	27.83%	56.90%	19.54%	11/3/2025 (Estimated)

Latest HZNP, BMY, ZTS, and RPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	RPRX Royalty Pharma	$1.10	$1.14	+$0.04	$0.05	$750.06 million	$578.67 million
8/5/2025	Q2 2025	ZTS Zoetis	$1.62	$1.76	+$0.14	$1.61	$2.41 billion	$2.46 billion
7/31/2025	Q2 2025	BMY Bristol Myers Squibb	$1.07	$1.46	+$0.39	$0.64	$11.32 billion	$12.27 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMY Bristol Myers Squibb	$2.48	5.27%	N/A	100.00%	17 Years
HZNP Horizon Therapeutics Public	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.88	2.46%	N/A	50.87%	5 Years
ZTS Zoetis	$2.00	1.29%	N/A	34.42%	14 Years

Latest HZNP, BMY, ZTS, and RPRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/18/2025	RPRX Royalty Pharma	quarterly	$0.22	2.48%	8/15/2025	8/15/2025	9/10/2025
6/17/2025	BMY Bristol Myers Squibb	quarterly	$0.62	5.25%	7/3/2025	7/3/2025	8/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMY Bristol Myers Squibb	2.54	1.21	1.11
HZNP Horizon Therapeutics Public	0.48	4.27	4.09
RPRX Royalty Pharma	0.74	1.26	1.26
ZTS Zoetis	1.05	1.76	1.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMY Bristol Myers Squibb	76.41%
HZNP Horizon Therapeutics Public	80.37%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
BMY Bristol Myers Squibb	0.07%
HZNP Horizon Therapeutics Public	2.20%
RPRX Royalty Pharma	18.90%
ZTS Zoetis	0.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMY Bristol Myers Squibb	34,100	2.04 billion	2.03 billion	Optionable
HZNP Horizon Therapeutics Public	2,115	228.99 million	223.96 million	Optionable
RPRX Royalty Pharma	80	583.17 million	472.95 million	Optionable
ZTS Zoetis	13,800	443.18 million	442.47 million	Optionable

HZNP, BMY, ZTS, and RPRX Headlines

Recent News About These Companies

Kayne Anderson Rudnick Investment Management LLC Lowers Position in Zoetis Inc. $ZTS

August 26 at 8:22 AM | marketbeat.com

In Depth Partners LLC Sells 9,596 Shares of Zoetis Inc. $ZTS

August 26 at 7:23 AM | marketbeat.com

Quantitative Investment Management LLC Takes Position in Zoetis Inc. $ZTS

August 26 at 7:08 AM | marketbeat.com

APG Asset Management N.V. Has $40.56 Million Stock Position in Zoetis Inc. $ZTS

August 26 at 6:10 AM | marketbeat.com

Northwestern Mutual Wealth Management Co. Purchases 24,462 Shares of Zoetis Inc. $ZTS

August 26 at 5:55 AM | marketbeat.com

Groupe la Francaise Purchases 10,947 Shares of Zoetis Inc. $ZTS

August 26 at 5:40 AM | marketbeat.com

Sax Wealth Advisors LLC Invests $646,000 in Zoetis Inc. $ZTS

August 26 at 5:39 AM | marketbeat.com

Allstate Corp Sells 5,688 Shares of Zoetis Inc. $ZTS

August 26 at 5:31 AM | marketbeat.com

Summit Financial LLC Sells 5,897 Shares of Zoetis Inc. $ZTS

August 26 at 5:11 AM | marketbeat.com

Price T Rowe Associates Inc. MD Decreases Stake in Zoetis Inc. $ZTS

August 26 at 4:58 AM | marketbeat.com

2 Reasons to Watch ZTS and 1 to Stay Cautious

August 25 at 10:08 AM | msn.com

Jump Financial LLC Grows Position in Zoetis Inc. $ZTS

August 25 at 8:57 AM | marketbeat.com

SVB Wealth LLC Has $5.14 Million Stock Holdings in Zoetis Inc. $ZTS

August 25 at 8:47 AM | marketbeat.com

RBO & Co. LLC Purchases 20,993 Shares of Zoetis Inc. $ZTS

August 25 at 8:16 AM | marketbeat.com

Bahl & Gaynor Inc. Raises Position in Zoetis Inc. $ZTS

August 25 at 8:16 AM | marketbeat.com

Douglass Winthrop Advisors LLC Grows Position in Zoetis Inc. $ZTS

August 25 at 7:13 AM | marketbeat.com

Zoetis: Why I Decided To Invest In The Stock

August 25 at 2:10 AM | seekingalpha.com

Zoetis: Why I Decided To Invest In The Stock

August 25 at 2:03 AM | seekingalpha.com

AlphaQuest LLC Increases Holdings in Zoetis Inc. $ZTS

August 24 at 9:28 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Purchased by Ameriprise Financial Inc.

August 24 at 7:27 AM | marketbeat.com

Zoetis Inc. $ZTS Shares Bought by Dorsey & Whitney Trust CO LLC

August 24 at 6:17 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HZNP, BMY, ZTS, and RPRX Company Descriptions

Bristol Myers Squibb NYSE:BMY

$47.10 -0.05 (-0.10%)

As of 03:31 PM Eastern

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Horizon Therapeutics Public NASDAQ:HZNP

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Royalty Pharma NASDAQ:RPRX

$35.82 -0.17 (-0.48%)

As of 03:31 PM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$155.02 -0.17 (-0.11%)

As of 03:31 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time